Cite
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
MLA
Auerswald,Guenter, et al. Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study). 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1190732079&authtype=sso&custid=ns315887.
APA
Auerswald,Guenter, Djambas Khayat, C., Stasyshyn,Oleksandra, Iosava,Genadi, Romashevskaya,Irina, Lã, pez,Marta J., Seifert,Wilfried, & Rogosch,Tobias. (2020). Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).
Chicago
Auerswald,Guenter, Claudia Djambas Khayat, Stasyshyn,Oleksandra, Iosava,Genadi, Romashevskaya,Irina, pez,Marta Julia Lã, Seifert,Wilfried, and Rogosch,Tobias. 2020. “Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1190732079&authtype=sso&custid=ns315887.